Changing the malaria treatment protocol policy in Timor-Leste: An examination of context, process, and actors' involvement

Health Research Policy and Systems

Volumn 11, Issue 1, 2013, Pages

  Martins, João S ^a,d   Zwi, Anthony B ^a,d   Hobday, Karen ^a   Bonaparte, Fernando ^b   Kelly, Paul M ^a,c,e  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Ministry of Health   (Timor-Leste)

^c The Australian National University   (Australia)

^d Faculty of Medicine and Health Sciences   (Timor-Leste)

^e Population Health Division   (Australia)

Author keywords

Evidence; Malaria treatment; Policy formulation; Policy process; Timor Leste; Treatment protocol

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; PYRIMETHAMINE PLUS SULFADOXINE;

ARTICLE; DRUG SUBSTITUTION; HEALTH CARE POLICY; HUMAN; MALARIA FALCIPARUM; MORBIDITY; PERCEPTION; PRACTICE GUIDELINE; RESEARCH ETHICS; TIMOR-LESTE; WORLD HEALTH ORGANIZATION;

ANTIMALARIALS; ARTEMISININS; CLINICAL PROTOCOLS; COOPERATIVE BEHAVIOR; DRUG COMBINATIONS; DRUG SUBSTITUTION; EAST TIMOR; ETHANOLAMINES; FLUORENES; HEALTH PLANNING ORGANIZATIONS; HEALTH POLICY; HUMANS; INTERINSTITUTIONAL RELATIONS; MALARIA, FALCIPARUM; POLICY MAKING; PYRIMETHAMINE; SULFADOXINE; TIME FACTORS;

EID: 84878354772     PISSN: None     EISSN: 14784505     Source Type: Journal    
DOI: 10.1186/1478-4505-11-16     Document Type: Article

References (37)

1. Ministerio da Saúde Protokol Pengobatan Malaria 2005, Ministerio da Saúde, RDTL, 2.
2. Ministry of Health. Malaria Treatment Protocol 2007, Democratic Republic of Timor-Leste: Ministry of Health, 3.
3. Malaria management protocol 2002, Dili, East Timor: Ministry of Health, Dili, East Timor and World Health Organization, 1.
4. Chen N, Baker J, Ezard N, Burns M, Edstein MD, Cheng Q. Short report: molecular evaluation of chloroquine treatment of uncomplicated plasmodium falciparum malaria in east timor. AmJTrop Med Hyg 2002, 67(1):64-66.
5. Guidelines for the Treatment of Malaria 2006, Geneva: The World Health Organization.
6. Bloland PB, Ettling M. Making malaria-treatment policy in the face of drug resistance. Ann Trop Med Parasitol 1999, 93(1):5-23.
7. Martins JS, Zwi AB, Hobday K, Bonaparte F, Kelly PM. The implementation of a new malaria treatment protocol in timor-leste: challenges and constraints. Health Policy Planning 2012, 27(8):677-686.
8. Araújo RM. Minister's Speech: launching of malaria treatment protocol for timor-leste 2007, 3.
9. Potter S, Subrahmanian R. Conceptualizing policy-related investigation. Finding Out Fast 1998, London: Sage Publications and The Open University, Thomas A, Chataway J, Wuyts M.
10. Walt G, Gilson L. Reforming the health sector in developing countries: the central role of policy analysis. Health Policy Planning 1994, 9(4):353-370.
11. Durrheim DN, Williams HA, Barnes K, Speare R, Sharp BL. Beyond evidence: retrospective study of factors influencing a malaria treatment policy change in two South African provinces. Critical Public Health 2003, 13(4):309-330.
12. Williams HA, Durrheim D, Shretta R. The process of changing national malaria treatment policy: lessons from country level studies. Health Policy Planning 2004, 19(6):356-370.
13. Djimde A, Plowe CV, Diop S, Dicko A, Wellems TE, Doumbo O. Use of antimalarial drugs in Mali: policy versus reality. AmJTrop Med Hyg 1998, 59:376-379.
14. Talisuna AO, Bloland P, D'Alessandro U. History, dynamics, and public health importance of malaria parasite resistance. Clin Microbiol Rev 2004, 17(1):235-254.
15. White NJ. Drug resistance in malaria. British Med Bull 1998, 54(3):703-715.
16. White NJ. Antimalarial drug resistance. J Clin Investig 2004, 113(8):1084-1092.
17. Grbich C. Qualitative data analysis: an introduction 2007, London: SAGE Publications.
18. Patton MQ. Qualitative research & evaluation methods 2002, Thousand Oaks. London: Sage Publications, 3.
19. Lin K. Meeting Minutes 2005, Malaria Working Group.
20. Palmer GR, Short SD. Health care & public policy: an australian analysis 2003, South Yara: MacMillan Publishers Australia Pty Ltd, 3.
21. Martins JS, Zwi AB, Kelly PM. Did the first global fund grant (2003-2006) contribute to malaria control and health system strengthening in Timor-Leste?. Malar J 2012, 11:237.
22. Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F, Ebsworth EP, Anstey NM, Tjitra E, Price RN. Tow fixed dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 2007, 369:757-765.
23. Report of the Twenty-Fourth Meeting of Ministers of Health of Countries of the South-East Asia Region. Dhaka, Bangladesh: World Health Organization 2006, New Delhi: WHO Regional Office for South-East Asia.
24. Revised malaria control strategy: focusing on a new paradigm 2007, Thimphu, Bhutan: WHO Regional Office for South-East Asia.
25. Martins JS, Zwi AB, Martins N, Kelly PM. Malaria control in Timor-Leste during a period of political instability: what lessons can be learned?. Confl Heal 2009, 3:11.
26. Zwi AB, Martins J, Grove NJ, Wayte K, Martins N, Kelly P. Timor-Leste Health Sector Resilience and Performance in a Time of Instability 2007, Sydney: The University of New South Wales.
27. Annual Report Year 3 Program. National Malaria Control Program 2007, Dili: The Ministry of Health, RDTL.
28. Shwe T, Lwin M, Aung S. Influence of blister packaging on the efficacy of artesunate + mefloquine over artesunate alone in community-based treatment of non-severe falciparum malaria in Myanmar. Bull World Health Organ 1998, 76(Suppl. 1):35-41.
29. Sipilanyambe N, Simon JL, Chanda P, Olumese P, Snow RW, Hamer DH. From chloroquine to artemether-lumefantrine: the process of drug policy change in Zambia. Malar J 2008, 7:25.
30. Walt G. Health Policy: An Introduction to Process and Power 1994, London and New Jersey: Zed Books.
31. Rungsihirunrat K, Sibley CH, Mungthin M, Na-Bangchang K. Geographical distribution of amino acid mutations in Plasmodium vivax DHFR and DHPS from malaria endemic areas of Thailand. AmJTrop Med Hyg 2008, 78(3):462-467.
32. Nair S, Williams JT, Brockman A, Paiphun L, Mayxay M, Newton PN, Guthmann JP, Smithuis FM, Hien TT, White NJ, Nosten F, Anderson TJ. A selective sweep driven by pyrimethamine treatment in Southeast Asian malaria parasites. Mol Biol Evol 2003, 20(9):1526-1536.
33. White NJ, Olliaro PL. Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. Parasitol Today 1996, 12(10):399-401.
34. Amin AA, Zurovac D, Kangawana BB, Greenfield J, Otieno DN, Akhwale WS, Snow RW. The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. Malar J 2007, 6:72.
35. Almeida A, Arez AP, Cravo PVL, Rosario VE. Analysis of genetic mutations associated with anti-malarial drug resistance in plasmodium falciparum from the democratic republic of East Timor. Malar J 2009, 8:59.
36. Ranson K, Poletti T, Bornemisza O, Sondrop E. Promoting Health Equity in Conflict-Affected Fragile States. The Conflict and Health Program 2007, London: London School of Hygiene and Tropical Medicine.
37. Zwi A, Ugalde A. Towards an epidemiology of political violence in the third world. Soc Sci Med 1989, 28(7):633-642.